Clinicopathological, functional, and immediate oncologic outcome assessment in men aged≤50 years with prostate cancer after robotic prostatectomy

Samadi, David B.; Sebrow, Dov; Hobbs, Adele R.; Bernstein, Adrien; Brajtbord, Jonathan S.; Lavery, Hugh J.; Jazayeri, Seyed Behzad

doi:10.1016/j.urolonc.2016.07.016

Cited by 12 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…What was interesting to observe was that, although young patients seemed to be in lower T stages pre-operatively, the pathological examination revealed rather similar staging, irrespective of the age group, as Samadi et al [ 17 ] also observed. As one would expect in this case, the rate of positive surgical margins in patients with pT3 stage that underwent bilateral nerve-sparing was higher in young patients.…”

Section: Discussionmentioning

confidence: 58%

See 1 more Smart Citation

Outcomes of robotic-assisted radical prostatectomy for patients in two extreme age-groups (< 50 years vs > 65 years)

Coman

Crişan

Andraș

et al. 2018

Medicine and Pharmacy Reports

View full text Add to dashboard Cite

Background and aimsTo assess the outcomes of robotic radical prostatectomy in two different age subgroups of pre-operatively potent patients: younger than 50 years and older than 65 years.MethodsWe included in the present study a number of 202 patients with prostate cancer divided into two groups: 99 patients older than 65 years (group 1) and 103 patients younger than 50 years (group 2).ResultsMore than half of the younger patients were low-risk vs 57% of the older patients who were high-risk. Overall positive surgical margins rate was 21.2% in group 1 vs 12.1% in group 2. The early biochemical recurrence at 6 months after radical prostatectomy was 4% in group 1 vs 11.6% in group 2. The continence rate at 6 months was similar between the two groups and was not correlated with the patients’ age (p=0.72), nerve-sparing (p=0.3 for group 1, p=0.92 for group 2) or pathological staging (overall p=0.81, p=0.89 in group 1 and p=0.63 in group 2). We observed a significantly higher rate of potency for patients in group 2 (91.5% vs 47.2%, p<0.0001). The most important factor associated with the regain of potency at 6 months after the procedure was the age of the patient (p<0.0001), independently of the type of nerve-sparing performed.ConclusionsAge seems to be the most important predictor of the regain of potency after robotic radical prostatectomy. Patients should be counseled accordingly in order to have realistic expectations about the functional results after robotic-assisted surgery.

show abstract

Section: Discussionmentioning

confidence: 58%

“…Other authors observed a delay in the return of continence and lower potency outcomes in the elderly population [ 15 , 16 ]. Age has been repeatedly shown to be an independent predictor of post-operative erectile function, possibly as a result of an improved baseline sexual function [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Outcomes of robotic-assisted radical prostatectomy for patients in two extreme age-groups (< 50 years vs > 65 years)

Coman

Crişan

Andraș

et al. 2018

Medicine and Pharmacy Reports

View full text Add to dashboard Cite

show abstract

“…After excluding case reports, non-published materials, editorials, reviews, commentaries, conference abstracts, and animal experiments, as well as irrelevant-topic studies with the first browse of title and abstract, the full-text of 191 papers, were read in detail to determine the eligibility. Finally, a total of 26 studies published from 2000 to 2019 with 391 068 patients in PSA era were included in the current study ( Table 1, Stable 1), 12,15,18,19,[22][23][24][25][26][27][28][29][30][31][32][33][34][39][40][41][42][43][44][45][46][47] and the majority of these studies were of relatively high quality with seven or more stars according to the NOS assessment ( Table 1). Seven out of the 26 studies which provided the data on comparing clinicopathological characteristics between younger (age ≤ 50) and older (age > 50) patients were suitable for odds ratio (OR) meta-analyses (Table 2).…”

Section: Literature Searchmentioning

confidence: 99%

“…Seven out of the 26 studies which provided the data on comparing clinicopathological characteristics between younger (age ≤ 50) and older (age > 50) patients were suitable for odds ratio (OR) meta-analyses (Table 2). [22][23][24]31,39,46,47 Furthermore, seven out of the 26 studies including 45 896 patients were with hazard ratio (HR) and 95% CI information for BCR prognosis and found to meet the inclusion criteria for meta-analysis. (Tables 3 and 4).…”

Section: Literature Searchmentioning

confidence: 99%

“…Since the publication of these reviews, more work regarding clinicopathologic characteristics of younger patients and the impact of early screening prognosis of PCa after RP have been reported. [22][23][24][25][26][27][28][29][30][31][32][33][34] In recent years, to avoid the overtreatment of indolent low-risk PCa detected by PSA screening, active surveillance (AS) treatment option has been increasingly adopted. 35 When the safety and feasibility of AS on younger patients were investigated by Salari et al, 36 they reported that AS outcome for men aged ≤ 60 years was similar to those patients at an age older than 60 years.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological characteristics of localized prostate cancer in younger men aged ≤ 50 years treated with radical prostatectomy in the PSA era: A systematic review and meta‐analysis

Zheng

Lin

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Objectives With the rapid increase in younger age prostate cancer (PCa) patients, the impact of younger age on decision‐making for PCa treatment needs to be revaluated in the new era. Materials and Methods A systematic literature search was performed using PubMed, EMBASE, and Web of Science up to October 2019 to identify the eligible radical prostatectomy (RP) studies focusing on understanding the impact of age on clinicopathological features and oncological prognosis in patients with localized PCa in PSA era. Meta‐analyses were conducted using available hazard ratios (HRs) from both univariate and multivariate analyses. Results Twenty‐six studies including 391 068 patients with RP treatments from the PSA era were included. Of these studies, age of 50 years old (age50) is the most commonly used cut‐off age to separate the younger patient group (including either age < 50 or age ≤ 50) from the older patient group. In these studies, the incidence of younger patients varied between 2.6% and 16.6% with a median of 8.3%. Younger patients consistently showed more favorable clinicopathological features correlated with better BCR prognosis. Meta‐analyses showed a 1.38‐fold improved BCR survival of younger patients in multivariate analysis. Among the high‐risk PCa patients, younger age was independently associated with worse oncological outcomes in multivariate analyses. Conclusion In this study, we found younger age correlated with favorable clinicopathological characteristics and better BCR prognosis in low‐ to intermediate‐risk patients. In high‐risk group patients, younger patients often showed significantly worse oncological outcomes. Our study results suggest that age 50 could be used as a practical cut‐off age to separate younger age patients from older age PCa patients.

show abstract

Epigenetics as a Key Factor in Prostate Cancer

Enikeeva,

Rafikova,

Sharifyanova

et al. 2024

Advanced Biology

View full text Add to dashboard Cite

Nowadays, prostate cancer is one of the most common forms of malignant neoplasms in men all over the world. Against the background of increasing incidence, there is a high mortality rate from prostate cancer, which is associated with an inadequate treatment strategy. Such a high prevalence of prostate cancer requires the development of methods that can ensure early detection of the disease, improve the effectiveness of treatment, and predict the therapeutic effect. Under these circumstances, it becomes crucial to focus on the development of effective diagnostic and therapeutic approaches. Due to the development of molecular genetic methods, a large number of studies have been accumulated on the role of epigenetic regulation of gene activity in cancer development, since it is epigenetic changes that can be detected at the earliest stages of cancer development. The presence of epigenetic aberrations in tumor tissue and correlations with drug resistance suggest new therapeutic approaches. Detection of epigenetic alterations such as CpG island methylation, histone modification, and microRNAs as biomarkers will improve the diagnosis of the disease, and the use of these strategies as targets for therapy will allow for greater personalization of prostate cancer treatment.

show abstract

Clinicopathological, functional, and immediate oncologic outcome assessment in men aged≤50 years with prostate cancer after robotic prostatectomy

Cited by 12 publications

References 31 publications

Outcomes of robotic-assisted radical prostatectomy for patients in two extreme age-groups (< 50 years vs > 65 years)

Outcomes of robotic-assisted radical prostatectomy for patients in two extreme age-groups (< 50 years vs > 65 years)

Clinicopathological characteristics of localized prostate cancer in younger men aged ≤ 50 years treated with radical prostatectomy in the PSA era: A systematic review and meta‐analysis

Epigenetics as a Key Factor in Prostate Cancer

Contact Info

Product

Resources

About